This document is an excerpt from the EUR-Lex website
Document 62009CN0066
Case C-66/09: Reference for a preliminary ruling from the Lietuvos Aukščiausiasis Teismas (Republic of Lithuania) lodged on 16 February 2009 — Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras
Case C-66/09: Reference for a preliminary ruling from the Lietuvos Aukščiausiasis Teismas (Republic of Lithuania) lodged on 16 February 2009 — Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras
Case C-66/09: Reference for a preliminary ruling from the Lietuvos Aukščiausiasis Teismas (Republic of Lithuania) lodged on 16 February 2009 — Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras
OJ C 90, 18.4.2009, p. 17–17
(BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
18.4.2009 |
EN |
Official Journal of the European Union |
C 90/17 |
Reference for a preliminary ruling from the Lietuvos Aukščiausiasis Teismas (Republic of Lithuania) lodged on 16 February 2009 — Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras
(Case C-66/09)
2009/C 90/27
Language of the case: Lithuanian
Referring court
Lietuvos Aukščiausiasis Teismas
Parties to the main proceedings
Claimant: Kirin Amgen, Inc.
Defendant: Lietuvos Respublikos valstybinis patentų biuras
Questions referred
1. |
Is the date, referred to in Article 19(2) of Regulation No 1768/92, (1) upon which that regulation enters into force to be understood for Lithuania as the date of its accession to the European Union? |
2. |
Should the answer to the first question be in the affirmative, what is the relationship between Article 19 and Article 7 of Regulation No 1768/92 when calculating the six-month period and which of those articles is it necessary to apply in a case? |
3. |
Did an authorisation to place a product on the market in the European Community enter into force unconditionally in the Republic of Lithuania from the date of its accession to the European Union? |
4. |
Should the answer to the third question be in the affirmative, can the entry into force of the authorisation to place the product on the market be equated to its grant for the purposes of Article 3(b) of Regulation No 1768/92? |
(1) Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products (OJ 1992 L 182, p. 1).